Body surface area and medication dosing in patients with heart failure with reduced ejection fraction

Multiple medications are proven to reduce morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), but data regarding personalized approaches to optimize medication dosing remain limited. Current treatment guidelines recommend up-titration to target or maximally...

Full description

Saved in:
Bibliographic Details
Published in:Trends in cardiovascular medicine 2021-02, Vol.31 (2), p.111-116
Main Authors: Brooksbank, Jeremy A., Greene, Stephen J., DeWald, Tracy A., Mentz, Robert J.
Format: Article
Language:English
Subjects:
Beta blockers
Blood pressure
Body mass index
Body surface area
Clinical trials
Comorbidity
Congestive heart failure
Dosage
Drug dosages
Ejection fraction
Heart failure
Medication dose
Morbidity
Mortality
Obesity
Patients
Pharmacokinetics
Renal function
Surface area
Target dose
Titration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple medications are proven to reduce morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), but data regarding personalized approaches to optimize medication dosing remain limited. Current treatment guidelines recommend up-titration to target or maximally tolerated doses of these medications, yet use and dosing remain suboptimal in clinical practice. Body surface area (BSA) is a readily available clinical metric, used for dosing many medications, closely associated with blood pressure, renal function, and vascular congestion, and may influence efficacy, safety, and tolerability of HFrEF medications. In this review, we examine the rationale, strengths/weaknesses, and potential utility of BSA as a means of optimizing HFrEF medication use and dosing.
ISSN:1050-1738
1873-2615
DOI:10.1016/j.tcm.2019.12.011